Drug · DIN 02478293
SOLIQUA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 12, 2018; first marketed September 12, 2018.
- Drug Identification Number (DIN)
- 02478293
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Insulin glargine and lixisenatide A10AE54
- Class
- Human
- Record last updated
- January 5, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| INSULIN GLARGINE | 100 UNIT | ML |
| LIXISENATIDE | 33 MCG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 6, 2018: NOC 21058New Drug Submission (NDS)